Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KYNU | Q16719 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | CTSK | P43235 | 5/20 | 0.56 |
| ▸ | CTSS | P25774 | 4/20 | 0.55 |
| ▸ | CTSL | P07711 | 3/20 | 0.55 |
| ▸ | CTSB | P07858 | 3/20 | 0.55 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.54 |
| ▸ | TACR1 | P25103 | 2/20 | 0.53 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2115471 | 1.00 | KYNU (0.63) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL3258258 | 1.00 | KYNU (0.63) | KYNUALDH1A1ALOX15CTSKCTSS | |
| Hydrochloric Acid SCHEMBL3258256 | 0.99 | KYNU (0.62) | KYNUALDH1A1ALOX15CTSKCTSS | |
| Hydrochloric Acid SCHEMBL3603216 | 0.99 | KYNU (0.62) | KYNUALDH1A1ALOX15CTSKCTSS | |
| Hydrochloric Acid SCHEMBL3603219 | 0.99 | KYNU (0.62) | KYNUALDH1A1ALOX15CTSKCTSS | |
| Trifluoroacetic Acid SCHEMBL5729191 | 0.93 | ALDH1A1 (0.58) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL29521405 | 0.91 | CTSK (0.56) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL29017554 | 0.91 | CTSK (0.56) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL30437751 | 0.91 | CTSK (0.56) | KYNUALDH1A1ALOX15CTSKCTSS | |
| Hydrochloric Acid SCHEMBL6933213 | 0.90 | CTSK (0.54) | KYNUALDH1A1ALOX15CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213117-A1 | PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2022-07-07 | — | — | US | disclosed |
| WO-2022129041-A1 | PRODRUGS OF 3-BENZOAMIDO-2-AMINOPROPIONIC ACID DERIVATIVES AS MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022129041-A1 | PRODRUGS OF 3-BENZOAMIDO-2-AMINOPROPIONIC ACID DERIVATIVES AS MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2022-06-23 | — | — | WO | disclosed |
| US-11358971-B2 | Prodrugs of modulators of the NMDA receptor | H. LUNDBECK A/S (DK) | 2022-06-14 | — | — | US | disclosed |
| EP-3994140-A1 | PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR | H. Lundbeck A/S (DK) | 2022-05-11 | — | — | EP | disclosed |
| CN-114008053-A | Prodrugs of NMDA receptor modulators | H.隆德贝克有限公司 | 2022-02-01 | — | — | CN | disclosed |
| US-20210047342-A1 | PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2021-02-18 | — | — | US | disclosed |
| US-10227331-B2 | Metallo-β-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180179190-A1 | METALLO-BETA-LACTAMASE INHIBITORS | Marck Sharp & Dohme Corp. (US) | 2018-06-28 | — | — | US | disclosed |
| US-8487108-B2 | Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8487108-B2 | Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20100048636-A1 | Aspartic Protease Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20090286791-A1 | Amide Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090275570-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| WO-2007070201-A1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| US-20040072860-A1 | Piperazin-2-one amides as inhibitors of factor xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-15 | — | — | US | disclosed |
| EP-1322643-A1 | PIPERAZIN-2-ONE AMIDES AS INHIBITORS OF FACTOR XA | Millennium Pharmaceuticals, Inc. (US) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002026734-A1 | PIPERAZIN-2-ONE AMIDES AS INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048636-A1 | Aspartic Protease Inhibitors | DNPEP, PEPD, SERPINB1 | KYNU 571/4885ALDH1A1 1416/4885ALOX15 2104/4885 |
| US-20090275570-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS | CHEK1, PDK1, CHEK2 | KYNU 3973/4885ALDH1A1 1677/4885ALOX15 4224/4885 |
| US-20090286791-A1 | Amide Compounds | DLAT, DGAT2, DGAT1 | KYNU 4016/4885ALDH1A1 231/4885ALOX15 1325/4885 |
| US-11358971-B2 | Prodrugs of modulators of the NMDA receptor | GRIN3A, GRIN1, GRIN2A | KYNU 53/4885ALDH1A1 2194/4885ALOX15 2137/4885 |
| US-20040072860-A1 | Piperazin-2-one amides as inhibitors of factor xa | F2, TFPI, TFPI2 | KYNU 1960/4885ALDH1A1 1970/4885ALOX15 2717/4885 |
| US-20210047342-A1 | PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR | GRIN3A, GRIN1, GRIN2A | KYNU 53/4885ALDH1A1 2194/4885ALOX15 2137/4885 |
| US-10227331-B2 | Metallo-β-lactamase inhibitors | ALPI, GAA, ZFX | KYNU 2481/4885ALDH1A1 310/4885ALOX15 1155/4885 |
| US-20180179190-A1 | METALLO-BETA-LACTAMASE INHIBITORS | ALPI, GAA, ZFX | KYNU 2465/4885ALDH1A1 319/4885ALOX15 1105/4885 |
| US-20220213117-A1 | PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR | GRIN3A, GRIN1, GRIN2A | KYNU 53/4885ALDH1A1 2194/4885ALOX15 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.